The London Biotechnology Show 2025 opened to a dynamic two-day run at ExCeL London, offering a rich blend of insightful conference sessions, cutting-edge exhibitions, and strategic networking opportunities. At the heart of it all, the conference featured some of the most impactful discussions on the current and future state of biotechnology.
Kicking off with remarks from Mr. Howard Dawber, Deputy Mayor of London, who shared London’s life sciences growth strategy, the conference brought together 75+ global experts across government, academia, pharma, and tech. Mr. Chris Johnson, Chief Scientific Advisor to the Department for Science, Innovation and Technology, followed with a keynote on innovation, cybersecurity, and regulation.
Go deeper with GlobalData
The two-day programme included high-level panels on:
- Automation in biotech labs with AAID, AWS, Ellab, Emerson
- AI/ML in diagnostics with Novo Nordisk and Microsoft
- Digital Health & Bioinformatics with speakers from Pfizer, Roche, IBM, NHS GCC, and Innovate UK
- Medical Devices & Biomedical Engineering, and
- Cell & Gene Therapy and Regenerative Medicine featuring CGT Catapult, Thermo Fisher, MHRA, and King’s College London.
Outside the conference rooms, the exhibition floor featured 100+ leading biotech brands and startups, including Thermo Fisher, Symbiotica Therapeutics, Discovery Park, and ACRO Biosystems. Attendees navigated through innovations in AI, diagnostics, biomedical materials, compliance services, and smart manufacturing.
The BioBridge London programme facilitated over 140 curated 1-on-1 meetings between solution providers and major buyers including Pfizer, AstraZeneca, Syngenta, and Lonza—cementing the show as a catalyst for high-value commercial partnerships.
Meanwhile, the Discovery Park Startup Showcase brought the spotlight to emerging innovators with pitch sessions, investor Q&As, and inspiring founder-focused discussions, energising the startup ecosystem and attracting packed audiences.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataWith strong feedback from participants and packed conference rooms, LBS 2025 has once again proven to be a key convergence point for global biotech leaders.
